Government Price-Setting Harms Patients, Prevents Cures
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer Among our many learnings from the COVID-19 pandemic is that a robust and effective medical innovation ecosystem is essential to researching and developing treatments, vaccines and cures for new and emerging threats to human health, as well as finding life-saving innovations for existing, […]
Biggest Need for New Jersey’s STEM Future: Keeping Our Talent Here
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer and Anthony S. Cicatiello, President of the R&D Council of New Jersey …
Rare Disease Day Highlights the Imperative to Support Biomedical Research
About 1 in 11 Americans, and 350 million people worldwide, suffer from a rare disease, defined as a disease affecting less than 200,000 people in the United States. …
Blame Middlemen, Insurers for Prices at the Drug Counter
The Star-Ledger’s recent editorial, “Drug prices are obscene, and (Gov. Phil) Murphy is blocking the smart solution,” left out key facts regarding the role of drug manufacturers in determining what patients pay for name-brand medicines. …
HealthCare Institute of New Jersey Statement on Vital Transformation Report on Price Controls
Trenton, July 29, 2022 ― Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning recent discussions in Washington on potential drug pricing legislation: “A new report by the consultancy Vital Transformation on the impact that price control policies under discussion in Washington would have […]
HealthCare Institute of New Jersey Statement on Vital Transformation Report on Price Controls
Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning recent discussions in Washington on potential drug pricing legislation.
HealthCare Institute of New Jersey Statement on Reconciliation Drug Pricing Legislation
Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning recent discussions in Washington on potential drug pricing legislation in a reconciliation package.
HealthCare Institute of New Jersey Announces New Board and Steering Committee Leadership
The HealthCare Institute of New Jersey (HINJ) has announced new officers of its Board of Trustees and the leadership of its Steering Committee, effective July 1.
Medical Technology is a Key Driver of New Jersey’s Life Sciences Engine
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer (Published in the print edition of the Asbury Park Press on Friday, May 13, 2022) New Jersey has long been globally recognized as the “Medicine Chest of the World” for its large and vibrant life sciences community. Our state proudly claims a broad swath […]
Pharmaceutical Rebates Benefit Insurers, PBMs More than Consumers — and That’s Wrong
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer Manufacturers frequently offer rebates that are passed through to consumers to reduce their purchase price of a product. For example, when buying a new car, the buyer gets the financial benefit of the manufacturer’s rebate rather than the dealer (middleman) keeping the rebate. […]